| Dec'19 | Dec'18 | |||||
|---|---|---|---|---|---|---|
Revenue | ||||||
63,354 | 34,557 | |||||
Cost of goods sold | ||||||
15,927 | 10,874 | |||||
Gross profit | ||||||
47,427 | 23,683 | |||||
Operating expenses: | ||||||
Research and development | ||||||
12,272 | 10,258 | |||||
Selling, general and administrative | ||||||
63,220 | 34,820 | |||||
Total operating expenses | ||||||
75,492 | 45,078 | |||||
Loss from operations | ||||||
-28,065 | -21,395 | |||||
Interest income | ||||||
1,656 | 189 | |||||
Interest expense | ||||||
4,952 | 4,361 | |||||
Other income (expense), net | ||||||
-21,054 | -12,063 | |||||
Nett loss | ||||||
-52,415 | -37,630 | |||||
Net loss attributable to non-controlling interest | ||||||
0 | -1 | |||||
Net loss attributable to Silk Road Medical, Inc. common stockholders | ||||||
-52,415 | -37,629 | |||||
Other comprehensive loss: | ||||||
Unrealized gains on investments, net | ||||||
2 | 0 | |||||
Net change in other comprehensive loss | ||||||
2 | 0 | |||||
Net loss and comprehensive loss | ||||||
-52,413 | -37,629 | |||||
Net loss per share, basic and diluted (in USD per share) | ||||||
-2.28 | -39.16 | |||||
Weighted average common shares used to compute net loss per share, basic and diluted (in shares) | ||||||
22,956 | 960 | |||||